Login to Your Account



Gilead Sciences strengthens cell therapy hand with Cell Design Labs buyout

By Marie Powers
News Editor

Friday, December 8, 2017

Three months after nabbing Kite Pharma Inc. for $11.9 billion, Gilead Sciences Inc. fine-tuned its cell therapy strategy with the structured acquisition of privately held Cell Design Labs Inc.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription